It has only been a few months since my first Seelos article (SEEL), but the company has been negotiating two deals to expand its pipeline and areas of study. The first deal was made in February with Bioblast Pharma (ORPN) concerning their mutant protein stabilization solution called Trehalose. Recently, the company signed a deal with UCLA for their peptide-inhibitor family for Parkinson's disease "PD".
It appears the company has added to its pipeline without committing to a large financial transaction. Then again, the company wouldn't be able to afford to give